Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Ltd. ( (AU:NOX) ) has provided an announcement.
Noxopharm Limited has announced significant progress in its quarterly activities, including a follow-on Material Transfer Agreement with an international company, highlighting growing interest in its Sofra technology platform. The company also reported that its novel drug candidate, SOF-SKN™, successfully passed preclinical tests, paving the way for a clinical trial aimed at treating autoimmune diseases like lupus. These developments position Noxopharm to capitalize on the expanding global RNA market and strengthen its industry standing.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian drug development company focused on creating innovative treatments for autoimmune diseases and leveraging its Sofra technology platform for vaccines and therapeutics. The company is actively involved in collaborations with international partners and research institutes to expand its market presence.
YTD Price Performance: -14.44%
Average Trading Volume: 93,652
Technical Sentiment Signal: Buy
Current Market Cap: A$22.5M
Learn more about NOX stock on TipRanks’ Stock Analysis page.